Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by jopatcloon Jul 18, 2024 3:11pm
106 Views
Post# 36138891

RE:👀Vision for Empowering Startups, Scale-Ups, and Investors

RE:👀Vision for Empowering Startups, Scale-Ups, and InvestorsRemenber this very good post Bart ! Embracing AI in Clinical Trials: The Future of Medical Research https://www.linkedin.com/pulse/embracing-ai-clinical-trials-future-medical-research-bart-hendriks-tndsf/

Insiders buy on the one market for one reason, they think its going up Insiders know!


Spotlight on Ventripoint's VMS+

Among the cutting-edge AI tools revolutionizing clinical trials in cardiology is Ventripoint's VMS+. This advanced medical imaging technology offers a unique value proposition by providing precise and comprehensive cardiac assessments. VMS+ excels in several key areas:

 

  1. Enhanced Imaging: VMS+ utilizes AI to generate accurate 3D models of the heart from standard 2D ultrasound images. This level of detail significantly improves the assessment of cardiac function and structure.
  2. Non-invasive Precision: Unlike traditional imaging techniques, VMS+ offers non-invasive precision that reduces the need for additional tests, making it easier and more comfortable for patients to participate in trials.
  3. Time Efficiency: The speed at which VMS+ can produce detailed cardiac analyses accelerates data collection and analysis, streamlining the clinical trial process.
  4. Comprehensive Data: By providing detailed insights into heart function, VMS+ supports the identification of subtle changes and trends, enhancing the overall quality of trial data.

 

The impact of Ventripoint's VMS+ on clinical trials is profound. By offering detailed, accurate, and non-invasive cardiac assessments, it not only improves the quality of data collected but also enhances patient comfort and compliance. This, in turn, leads to more robust and reliable trial outcomes, accelerating the development of new cardiovascular therapies.

Conclusion

While AI's full integration into daily clinical practice may still be on the horizon, its application in clinical trials, particularly in cardiology, is not only feasible but also highly beneficial today. By leveraging AI tools like Ventripoint's VMS+, we can enhance the efficiency, accuracy, and outcomes of clinical trials, paving the way for faster and more cost-effective drug development.

As we continue to advance, let’s embrace AI in clinical trials to unlock its full potential and drive the future of medical research forward.

<< Previous
Bullboard Posts
Next >>